DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

About this update from Diamedica Therapeutics Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":631,"url":"https://media.zenfs.com/en/business-wire.com/2ec136bda664cc01ac678839f96999db"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bKUhbyEXlZ93Ck9TvqqaoA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2ec136bda664cc01ac678839f96999db","width":960,"height":303},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/SU2qajhRog57GU4UfLjCJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/2ec136bda664cc01ac678839f96999db","width":1200,"height":379}},"lazy":false},{"type":"text","content":"Conference Call and Webcast May 14 at 8:00 AM Eastern Time / 7:00 AM Central Time","length":81,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Topline DM199 Preeclampsia Phase 2 Part 1A Proof of Concept Results Expected in Near Term and Phase 2 Part 1B Expected to Initiate in Q3 2025","length":141,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"KOL Event Scheduled for May 28, 2025 to Discuss the Disease of Preeclampsia and the Ongoing DM199 Phase 2 Study Design","length":118,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Acute Ischemic Stroke Phase 2/3 Program Enrollment Progressing as Planned","length":73,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash Runway into Q3 2026","length":24,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":356,"olType":false},{"type":"text","content":"MINNEAPOLIS, May 13, 2025--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the quarter ended March 31, 2025. Management will host a conference call Wednesday, May 14, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2025 financial results.","length":490,"tagName":"p"},{"type":"text","content":"Preeclampsia Phase 2 Clinical Developments Parts 1A and B","length":57,"tagName":"p"},{"type":"text","content":"Dosing in the Phase 2 Part 1A trial of DM199 for preeclampsi...

More updates from Diamedica Therapeutics Inc.